Microbot Medical announced that it has filed an Investigational Device Exemption, IDE, application with the US Food and Drug Administration, FDA. The IDE application follows the completion of multiple preclinical activities performed to provide preliminary safety and effectiveness information, and its approval by the FDA would allow the company to commence its pivotal human clinical trial in the United States. “This is an important milestone for the company, and it is another step forward in our journey to achieve FDA clearance for the LIBERTY Endovascular Robotic Surgical System,” said Harel Gadot, CEO, President and Chairman of Microbot Medical.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MBOT:
- Microbot Medical Seeks FDA Approval for Clinical Trial
- Microbot Medical Settles: Regulation FD Disclosure Update
- Microbot Medical Inc Conducts Private Equity Sale
- Microbot Medical Resolves Litigation Through Settlement Agreement
- Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
